Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

OBJECTIVES: In the ‘Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism’ (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Lisa A, van der Velden, Annette W G, van Hulst, Marinus, Postma, Maarten J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678368/
https://www.ncbi.nlm.nih.gov/pubmed/33444193
http://dx.doi.org/10.1136/bmjopen-2020-039057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678368/
https://www.ncbi.nlm.nih.gov/pubmed/33444193
http://dx.doi.org/10.1136/bmjopen-2020-039057

Ejemplares similares